Loncastuximab Tesirine Production Cost Reports

The report provides a detailed analysis essential for establishing a loncastuximab tesirine production plant. It encompasses all critical aspects necessary for loncastuximab tesirine production, including the cost of loncastuximab tesirine production, loncastuximab tesirine plant cost, loncastuximab tesirine production costs, and the overall loncastuximab tesirine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a loncastuximab tesirine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Loncastuximab tesirine, marketed as Zynlonta, is a CD19-directed antibody-drug conjugate approved to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma in adults after at least two prior systemic therapies. It has an FDA accelerated approval granted in 2021 based on the LOTIS-2 trial showing a 48% overall response rate. Its structure links a humanised monoclonal antibody to a potent pyrrolobenzodiazepine dimer toxin via a protease-cleavable linker, enabling targeted delivery to CD19-expressing B-cells for cytotoxic effects.

The market drivers for loncastuximab tesirine include the rising incidence of lymphomas, such as diffuse large B-cell lymphoma (DLBCL), fuelled by ageing populations, immune suppression, environmental factors, and genetic predispositions, which increase demand for targeted therapies like this CD19-directed antibody-drug conjugate. Regulatory approvals, including FDA accelerated approval in 2021 and ongoing expansions into earlier treatment lines and combinations, along with growth in clinical trials and combination therapies, further propel market growth.

The expanding DLBCL market and the broader antibody-drug conjugate sector support Zynlonta's potential amid increasing awareness, diagnosis rates, and innovation in oncology. High drug costs, including acquisition expenses, along with associated administration, premedication, monitoring, prophylactic treatments, and adverse event management, drive budget impact models for formulary inclusion, influencing industrial loncastuximab tesirine procurement.

Raw Material for Loncastuximab Tesirine Production

According to the loncastuximab tesirine production plant project report, the various raw materials for loncastuximab tesirine production include humanized anti-CD19 monoclonal antibody and tesirine.

Production Process of Loncastuximab Tesirine

The extensive loncastuximab tesirine production cost report consists of the following major industrial production process:

1. Production via recombinant DNA technology: The production process of loncastuximab tesirine occurs by first producing the humanised IgG1 kappa anti-CD19 monoclonal antibody via recombinant DNA technology in Chinese hamster ovary (CHO) mammalian cells under controlled bioreactor conditions. The process is followed by purification through protein A chromatography, viral inactivation, and polishing steps to yield a high-purity antibody. The small-molecule tesirine (SG3249), a protease-cleavable valine-alanine linker attached to the pyrrolobenzodiazepine dimer cytotoxin SG3199, is synthesised separately through multi-stage chemical organic reactions, including maleimide activation. In the next step, the conjugate is formed via site-specific chemical conjugation of reduced antibody cysteines to tesirine, achieving an average drug-to-antibody ratio of 2.3. The final step involves purification, sterile filtration, and lyophilisation.

Properties of Loncastuximab tesirine

Loncastuximab tesirine (Zynlonta) is a CD19-directed antibody-drug conjugate with a molecular weight of 151 kDa and an average drug-to-antibody ratio of 2.3. It consists of a humanised IgG1 kappa monoclonal antibody covalently linked via a protease-cleavable valine-alanine linker to SG3199, a pyrrolobenzodiazepine dimer cytotoxic agent that forms interstrand DNA crosslinks upon lysosomal cleavage. It appears as a sterile, white to off-white lyophilised powder (10 mg/vial with histidine buffer and sucrose excipients), reconstituting to a 5 mg/mL solution at pH ~6.0 for IV infusion, requiring 2-8 degree Celsius storage, light protection, and 24-hour refrigerated stability post-reconstitution. It is chemically tailored for targeted oncology delivery and has non-linear pharmacokinetics with rapid clearance unaffected by mild-moderate renal impairment.